Post-partum haemorrhage and tranexamic acid: a global issue

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Maternal Health

Background:

• Post-partum haemorrhage (PPH) is a primary cause of maternal mortality globally, particularly in low-income countries.
• Pregnancy-related changes in haemostasis and fibrinolysis contribute to PPH.
• The efficacy of tranexamic acid (TxA) in PPH management was previously less established.

Purpose of the Study:

• To evaluate the impact of the World Maternal Antifibrinolytic (WOMAN) trial on the use of tranexamic acid (TxA) for PPH.
• To assess the safety and effectiveness of intravenous TxA in reducing mortality associated with PPH.

Main Methods:

• The study discusses findings from the recently published WOMAN trial.
• Intravenous TxA was administered to women experiencing PPH, compared against a placebo group.

Main Results:

• Intravenous TxA significantly reduced bleeding deaths in women with PPH (Risk Ratio 0.81).
• No increased risk of thrombotic events was observed in mothers or breast-fed infants.

Conclusions:

• Intravenous TxA is a safe and effective treatment for PPH, warranting widespread clinical adoption.
• Further research into oral/topical TxA and pre-emptive dosing is needed for resource-constrained settings.